PEG-MGF vs Thymosin Beta-4
limited vs Well Studied
synergistic Different regenerative pathways may enhance tissue repair through multiple mechanisms.
Molecular Data
PEG-MGF Thymosin Beta-4
Weight ~2,888 Da 4,963.44 Da
Half-life 48-72 hours (via PEGylation) Dose-dependent; relatively short (exact values not established)
Chain 24 amino acids 43 amino acids
Type IGF-1Ec splice variant C-terminal peptide Thymosin peptide
Key Benefits
PEG-MGF
01 Extended half-life through PEGylation
02 Satellite cell activation for muscle repair
03 Recovery support following mechanical stress
04 Potential neuroprotection against oxidative stress
Thymosin Beta-4
01 Systemic regenerative effects
02 Proven clinical efficacy
03 Optimal bioavailability for tissue repair
04 Promotes angiogenesis
05 Reduces inflammation
Dosing Protocols
PEG-MGF
200-400mcg per injection / 2-3x weekly, ideally post-workout
General Recovery 200mcg 2-3x weekly
Targeted Muscle Recovery 200-400mcg Post-workout, 2-3x weekly
Injury Recovery 200-400mcg 2-3x weekly
Conservative Protocol 100-200mcg 2x weekly
Thymosin Beta-4
2-6mg per injection (varies by protocol and severity) / Daily for acute healing, 2x weekly for maintenance/chronic conditions
Acute Wound Healing 1.6mg Daily
Cardiac Protection 42mg Single dose
Chronic Tissue Repair 6mg Twice weekly
Neurological Recovery 30mg Three times over 72 hours
General Regeneration 2-5mg Daily or every other day
Side Effects
PEG-MGF
Injection site soreness
Mild fatigue
Thymosin Beta-4
Mild injection site reactions
Local inflammation at injection sites
Contraindications
Any history of cancer or neoplastic disease
Pregnancy or breastfeeding
Uncontrolled diabetes or severe hyperglycemia
Active chemotherapy treatment
Severe systemic allergies to peptides
Research Evidence
PEG-MGF Thymosin Beta-4
Status limited Well Studied
References 3 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.